Clinical trials: Invasive Carcinoma
Bladder Cancer
Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be…
- Trial name
- NCT00380029
- Testing
- Erlotinib, Radical Cystectomy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
This phase II trial tests the effect of intravesical nadofaragene firadenovec in combination with gemcitabine, cisplatin and durvalumab before (neoadjuvant) radical cystectomy (RC) in treating patients with muscle invasive…
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- TRIFECTA (NCT07332351)
- Testing
- Nadofaragene Firadenovec, Durvalumab, Gemcitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Washington
Carcinoma, Lobular
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular Carcinoma
This study aims to explore the diagnostic validity of [18F]FES PET/CT for the evaluation of axillary lymph node metastasis in patients with invasive lobular breast cancer having clinically suspected or confirmed axillary lymph…
- Trial name
- NCT05960201
- Testing
- [18F]fluoroestradiol (FES)
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Asan Medical Center
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma
Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
This randomized phase II trial studies how well erlotinib hydrochloride with or without carboplatin and paclitaxel works in treating patients with stage III-IV non-small cell lung cancer.
- Conditions
- Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Malignant Pericardial Effusion, Malignant Pleural Effusion
- Trial name
- NCT00126581
- Testing
- Carboplatin, Erlotinib, Erlotinib Hydrochloride
- Where
- 96 sites in United States
- Volunteers
- 188 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma of Urinary Bladder, Superficial
Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC
In the proposed study the investigators aim to evaluate the effect of the standard of care dose (40mg) of MMC mixed with TC-3 gel (with sustained release mechanism on the drug) on low risk recurrent NMIBC lesions and to compare…
- Trial name
- OPTIMA (NCT01803295)
- Testing
- 40 mg MMC gel, Standard of care MMC mixed with water, 80 mg MMC gel
- Where
- 13 sites in Israel, Italy and 2 more
- Volunteers
- 80 people
- Sponsor
- UroGen Pharma Ltd.
Urinary Bladder Neoplasms, Neoplasm Metastasis
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer.
- Conditions
- Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
- Trial name
- FORAGER-1 (NCT05614739)
- Testing
- Vepugratinib, Pembrolizumab, enfortumab vedotin
- Where
- 82 sites in United States, Australia and 12 more
- Volunteers
- 677 people
- Sponsor
- Eli Lilly and Company
NMIBC
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) who are BCG Naïve or BCG Unresponsive and are considered ineligible for or have refused to undergo radical cystectomy, will receive RC48-ADC in…
- Trial name
- NCT05943379
- Testing
- RC48-ADC in Combination with gemcitabine
- Where
- China
- Volunteers
- 85 people
- Sponsor
- RemeGen Co., Ltd.
Bladder Carcinoma
Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection
The primary objective of the study is to assess the bladder cancer recurrence free rate, according to a phase II pilot study, of intravesical instillation of sequential BCG and EMDA/MMC after TUR.
- Trial name
- NCT02202044
- Testing
- Intravesical BCG and EMDA/MMC
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Non-muscle-invasive Bladder Cancer
Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer
Bacillus Calmette-Guerin (BCG) is the standard of care for high-risk patients with non-muscle invasive bladder cancer (NMIBC) after transurethral tumor resection.
- Trial name
- NCT05671900
- Testing
- Gemcitabine 1000 mg, Docetaxel 37.5g
- Where
- Croatia
- Volunteers
- 70 people
- Sponsor
- Clinical Hospital Centre Zagreb
Muscle-Invasive Bladder Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma
Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
Observational study on the quality of life and pathological state of patients underwent radical cystectomy.
- Conditions
- Muscle-Invasive Bladder Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma, Bladder Cancer TNM Staging, Bladder Cancer Stage IIa
- Trial name
- NCT06170177
- Testing
- Radical Cystectomy
- Where
- Italy
- Volunteers
- 4,000 people
- Sponsor
- IRCCS San Raffaele
Urothelial Carcinoma Bladder
JAM3 as a Prognostic Biomarker in Muscle-Invasive Urothelial Carcinoma: Correlation With Therapeutic Response, and Survival Outcomes
Bladder cancer(BC) is the 10th most common cancer globally, with a higher incidence in males than females, being the 6th most common cancer in men with high mortality, causing a societal burden worldwide.
- Trial name
- NCT06901934
- Testing
- junctional adhesion molecule3 expression by immunhistochemistry
- Volunteers
- 40 people
- Sponsor
- Zeinab Yahia Zaki
Muscle-invasive Bladder Cancer
Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging
Bladder cancer is the fifth most common cancer in Canada and there has been relatively little progress in altering its clinical course over the last three decades.
- Trial name
- PET MUSE (NCT02462239)
- Testing
- Whole-body FDG PET-CT
- Where
- 6 sites in Canada
- Volunteers
- 292 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Carcinoma, Breast Ductal Carcinoma In Situ
Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer
This trial studies the effect of an electronic health (eHealth) support program called PACK Health on patient reported health outcomes in patients with breast cancer.
- Conditions
- Breast Carcinoma, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Recurrent Breast Carcinoma
- Trial name
- NCT04022772
- Testing
- Best Practice, Medical Chart Review, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Invasive Ductal Breast Carcinoma
Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer
This study examines retrospective clinical data on patients diagnosed with breast cancer and monitor their response to neoadjuvant chemotherapy, incidence of locoregional recurrence, distant metastasis, and disease-free survival.
- Conditions
- Breast Cancer, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma
- Trial name
- NCT04021069
- Testing
- Radiomic, pathomic, and clinical markers
- Where
- Canada
- Volunteers
- 800 people
- Sponsor
- Sunnybrook Health Sciences Centre
Early-stage Breast Cancer, Invasive Ductal Carcinoma of Female Breast
Radiation After No Axillary Nodal Sampling
This is a single arm, pilot, prospective study to evaluate the safety of partial breast irradiation in women who undergo breast conserving surgery without sentinel lymph node biopsy (SLNB) or axillary lymph node dissection…
- Trial name
- RADIANS (NCT07723209)
- Testing
- Partial Breast Irradiation (PBI)
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- NYU Langone Health
Non-small Cell Lung Cancer, Minimal Residual Disease
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small cell lung cancer.
- Conditions
- Non-small Cell Lung Cancer, Minimal Residual Disease, Adaptive Treatment
- Trial name
- NCT06930807
- Testing
- Adaptive postoperative management based on minimal residual disease
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking University People's Hospital
Invasive Breast Carcinoma, Recurrent Breast Carcinoma
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
This randomized phase III trial studies tamoxifen citrate or letrozole together with bevacizumab to see how well it works compared with tamoxifen citrate or letrozole alone in treating women with stage IIIB or stage IV breast…
- Conditions
- Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT00601900
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Letrozole
- Where
- 522 sites in United States, Puerto Rico
- Volunteers
- 394 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Invasive Ductal, Breast
Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)
It is a phase III trial to explore the efficacy and safety of vinorelbine plus capecitabine (NX) and docetaxel plus capecitabine (TX) as first line treatment followed by capecitabine alone till Progressive Disease(PD).
- Trial name
- NCT01126138
- Testing
- Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine, Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese Academy of Medical Sciences
Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
This is a single-arm, phase 1/2a study of formulated paclitaxel in subjects with low-grade, noninvasive papillary carcinoma (stage Ta) of the bladder.
- Conditions
- Bladder Cancer Cell Transitional, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, Urinary Bladder
- Trial name
- NCT03081858
- Testing
- TSD-001
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Lipac Oncology LLC
Non-Invasive Bladder Urothelial Carcinoma
Intravesical BCG: is the Urinary Bladder Ready to Receive it
Prospective cohort and Prospective observational study which aims To define the healing time-frame of the resected area of the bladder after TURBT.
- Trial name
- NCT05335512
- Volunteers
- 100 people
- Sponsor
- Tata Memorial Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.